Protective Effect of Pediococcus pentosaceus LI05 Against Clostridium difficile Infection in a Mouse Model
- 2018-10-09
- Frontiers in Microbiology 9
- Qiaomai Xu
- Silan Gu
- Yunbo Chen
- Jiazheng Quan
- L. Lv
- Da-Zhi Chen
- B. Zheng
- Lichen Xu
- Lanjuan Li
- PubMed: 30356740
- DOI: 10.3389/fmicb.2018.02396
Abstract
Clostridium difficile infection (CDI) is a major cause of infectious diarrhea among hospitalized patients. Probiotics could be instrumental in restoring the intestinal dysbiosis caused by CDI. Here, we examined the protective effect of Pediococcus pentosaceus LI05 in a mouse CDI model. C57BL/6 mice were administrated P. pentosaceus LI05 (LI05 group) or sterile anaerobic PBS (CDI group) everyday for 14 days. Mice were exposed to antibiotics cocktail for 5 days; then challenged with C. difficile strain VPI10463. Mice were monitored daily for survival and weight loss. Colonic tissue and serum samples were assessed for intestinal histopathology, intestinal barrier function and systemic inflammation. The oral administration of P. pentosaceus LI05 improved the survival rate and alleviated the histopathological impact of C. difficile. Compared to the CDI group, the levels of inflammatory mediators in the colon as well as inflammatory cytokines and chemokines in serum were substantially attenuated in the LI05 group. P. pentosaceus LI05 alleviated the CDI-induced of disruption of ZO-1, occludin and claudin-1. Additionally, fecal microbiome analysis showed an enrichment in the abundance of the Porphyromonadaceae and Rikenellaceae, while, the relative abundance of Enterobacteriaceae were decreased. Our results demonstrated that the preventive effect of P. pentosaceus LI05 against CDI was mediated via improving tight junction proteins and down-regulating the inflammatory response. Therefore, P. pentosaceus LI05 could be a promising probiotic in CDI.
Keywords: Clostridium difficile; inflammatory cytokines; intestinal dysbiosis; probiotics; tight junction proteins.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Pediococcus pentosaceus MAK99P15P | Improved Intestinal Barrier Function | Beneficial | Moderate |
Pediococcus pentosaceus MAK99P15P | Improved Intestinal Histopathology | Beneficial | Moderate |
Pediococcus pentosaceus MAK99P15P | Improved Microbiota Composition | Beneficial | Moderate |
Pediococcus pentosaceus MAK99P15P | Improved Survival Rate | Beneficial | Moderate |
Pediococcus pentosaceus MAK99P15P | Reduced Inflammatory Mediators | Beneficial | Large |
Pediococcus pentosaceus PP06 | Improved Intestinal Barrier Function | Beneficial | Moderate |
Pediococcus pentosaceus PP06 | Improved Survival Rate | Beneficial | Moderate |
Pediococcus pentosaceus PP06 | Reduced Inflammation Levels | Beneficial | Large |
Pediococcus pentosaceus PP06 | Restored Gut Microbiome Balance | Beneficial | Moderate |